Related Experiment Video

Updated: Jul 19, 2026

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models
10:19

Evaluation of Biomaterials for Bladder Augmentation using Cystometric Analyses in Various Rodent Models

Published on: August 9, 2012

Preliminary study of the safety and efficacy of extended-release oxybutynin in children

Katrin Youdim1, Barry A Kogan

  • 1Division of Urology, Albany Medical College, Albany, New York 12208, USA.

Urology
|March 7, 2002
PubMed

Insights

Extended-release oxybutynin is safe and effective for treating bladder dysfunction in children, showing improved incontinence and voiding. This new formulation offers benefits over traditional oxybutynin with better compliance and fewer side effects.

Area of Science:

  • Pediatric Urology
  • Pharmacology
  • Clinical Medicine

Background:

  • Pediatric bladder dysfunction often presents challenges with traditional oxybutynin due to side effects.
  • A novel extended-release formulation of oxybutynin aims to improve tolerability and efficacy.
  • Previous evaluations of extended-release oxybutynin have not included pediatric populations.

Purpose of the Study:

  • To assess the safety and efficacy of extended-release oxybutynin in pediatric patients with bladder dysfunction.
  • To compare the outcomes of extended-release oxybutynin with traditional immediate-release oxybutynin in children.
  • To evaluate patient and family compliance and satisfaction with the extended-release formulation.

Main Methods:

  • A retrospective study involving 25 children with bladder dysfunction treated with extended-release oxybutynin.
  • Patients included those with neurogenic bladder and those with idiopathic urgency and incontinence.
  • Semiquantitative assessments of efficacy, side effects, and compliance were obtained from patients and families.

Main Results:

  • All 25 patients demonstrated improvement in incontinence and/or voiding dysfunction.
  • 48% of patients experienced no side effects; common side effects included dry mouth, constipation, heat intolerance, and drowsiness.
  • Extended-release oxybutynin showed equal or greater efficacy with similar or fewer side effects compared to immediate-release oxybutynin, notably less dry mouth.
  • Patient and family satisfaction was high, with 21 of 25 patients continuing treatment.

Conclusions:

  • Extended-release oxybutynin is a safe and effective treatment option for children with bladder dysfunction.
  • The extended-release formulation offers advantages over immediate-release oxybutynin, including improved compliance and tolerability.
  • This preliminary evaluation supports the use of extended-release oxybutynin in pediatric urology practice.
Abstract

More Related Videos

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling07:11

Assessment of the Efficacy of An Osteopathic Treatment in Infants with Biomechanical Impairments to Suckling

Published on: February 5, 2019

An Immature Murine Model of Reversible Unilateral Ureteral Obstruction06:37

An Immature Murine Model of Reversible Unilateral Ureteral Obstruction

Published on: April 4, 2025

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...